Thermo Fisher Scientific Inc.
Financials
Valuation Metrics
Thermo Fisher Scientific Inc.'s Market Cap is $242.01B. At end of 2025 it was $217.87B. Ranked #60 of 3,121 in US market (top 2%), #37 of 1,658 on NYSE (top 2%), #2 of 205 in Health Care Equipment & Services (top 1.0%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $242.01B | US#60/3,121 Sec#2/205 |
| Revenue | $46.34B | US#139/3,121 Sec#12/205 |
| Net Income | $6.98B | US#112/3,121 Sec#2/205 |
| Total Assets | $113.17B | US#158/3,121 Sec#5/205 |
| Net Assets | $52.68B | US#79/3,121 Sec#3/205 |
| Employees | 125,000 | US#80/3,121 Sec#4/205 |
| Value | ||
| P/E | 34.68x | US#1,711/3,121 Sec#74/205 |
| P/B | 4.59x | US#2,153/3,121 Sec#127/205 |
| PEG | 5.80x | US#1,211/3,121 Sec#64/205 |
| P/S | 5.22x | US#2,335/3,121 Sec#153/205 |
| EV/EBITDA | 25.65x | US#2,128/3,121 Sec#108/205 |
| FCF Yield | 3.02% | US#1,832/3,121 Sec#107/205 |
| Profitability | ||
| ROE | 13.25% | US#1,025/3,121 Sec#51/205 |
| ROA | 6.17% | US#893/3,121 Sec#58/205 |
| Op. Margin | 17.69% | US#1,044/3,121 Sec#34/205 |
| Revenue Growth | 7.23% | US#1,561/3,121 Sec#110/205 |
| Earnings Growth | 5.98% | US#1,176/3,121 Sec#65/205 |
| Financial Health | ||
| Debt Ratio | 114.82% | US#1,230/3,121 Sec#115/205 |
| Total Debt | $42.55B | US#112/3,121 Sec#4/205 |
| FCF | $7.32B | US#116/3,121 Sec#6/205 |
| Cash | $4.06B | US#243/3,121 Sec#14/205 |
| Current Ratio | 1.55x | US#1,622/3,121 Sec#143/205 |
| Net Debt/EBITDA | 3.52x | US#1,739/3,121 Sec#108/205 |
| Dividend | ||
| Div. Yield | 0.27% | US#1,616/3,121 Sec#50/205 |
| Div. Growth | 10.83% | US#469/3,121 Sec#14/205 |
| Performance | ||
| 1Y Return | 35.47% | US#722/3,121 Sec#62/205 |
| 1M Return | 6.14% | US#199/3,121 Sec#29/205 |
| From 52W High | -1.86% | US#38/3,121 Sec#10/205 |
| 1Y MDD | -31.45% | US#1,523/3,121 Sec#72/205 |
| Trading | ||
| Volume | 2,287,347 shares | US#522/3,121 Sec#26/205 |
| Trading Value | $1.49B | US#36/3,121 Sec#1/205 |
| Per Share | ||
| EPS | $18.78 | US#98/3,121 Sec#10/205 |
| BPS | $141.75 | US#51/3,121 Sec#6/205 |
Company Info
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.